Trials / Completed
CompletedNCT03473925
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).
Conditions
- Solid Tumors
- Non-small Cell Lung Cancer
- Castration Resistant Prostate Cancer
- Microsatellite Stable Colorectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Navarixin | Oral capsules |
| BIOLOGICAL | Pembrolizumab | Intravenous infusion |
Timeline
- Start date
- 2018-04-10
- Primary completion
- 2021-05-19
- Completion
- 2021-05-19
- First posted
- 2018-03-22
- Last updated
- 2024-08-28
- Results posted
- 2022-06-29
Locations
14 sites across 5 countries: United States, Australia, Canada, Israel, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03473925. Inclusion in this directory is not an endorsement.